Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome

被引:165
作者
Vitale, Cristiana [1 ]
Mercuro, Giuseppe [2 ]
Castiglioni, Carlotta [1 ]
Cornoldi, Alessandra [1 ]
Tulli, Arianna [1 ]
Fini, Massimo [1 ]
Volterrani, Maurizio [1 ]
Rosano, Giuseppe M. C. [1 ]
机构
[1] IRCCS San Raffaele, Dept Med Sci & Rehabil, Rome, Italy
[2] Univ Cagliari, Dept Cardiol, Calgliari, Italy
关键词
D O I
10.1186/1475-2840-4-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Metabolic syndrome is a cluster of common cardiovascular risk factors that includes hypertension and insulin resistance. Hypertension and diabetes mellitus are frequent comorbidities and, like metabolic syndrome, increase the risk of cardiovascular events. Telmisartan, an antihypertensive agent with evidence of partial peroxisome proliferator-activated receptor activity-gamma (PPAR gamma) activity, may improve insulin sensitivity and lipid profile in patients with metabolic syndrome. Methods: In a double-blind, parallel-group, randomized study, patients with World Health Organization criteria for metabolic syndrome received once-daily doses of telmisartan (80 mg, n = 20) or losartan (50 mg, n = 20) for 3 months. At baseline and end of treatment, fasting and postprandial plasma glucose, insulin sensitivity, glycosylated haemoglobin (HBA(1c)) and 24-hour mean systolic and diastolic blood pressures were determined. Results: Telmisartan, but not losartan, significantly (p < 0.05) reduced free plasma glucose, free plasma insulin, homeostasis model assessment of insulin resistance and HbA(1c). Following treatment, plasma glucose and insulin were reduced during the oral glucose tolerance test by telmisartan, but not by losartan. Telmisartan also significantly reduced 24-hour mean systolic blood pressure (p < 0.05) and diastolic blood pressure (p < 0.05) compared with losartan. Conclusion: As well as providing superior 24-hour blood pressure control, telmisartan, unlike losartan, displayed insulin-sensitizing activity, which may be explained by its partial PPAR gamma activity.
引用
收藏
页数:8
相关论文
共 38 条
[11]  
Genuth S, 2003, DIABETES CARE, V26, P3160
[12]   Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus [J].
Gress, TW ;
Nieto, FJ ;
Shahar, E ;
Wofford, MR ;
Brancati, FL .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (13) :905-912
[13]   Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report [J].
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, R ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Cleeman, JI ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ ;
Keller, SA ;
Jehle, AJ .
CIRCULATION, 2002, 106 (25) :3143-3421
[14]   A prospective analysis of the HOMA model - The Mexico City Diabetes Study [J].
Haffner, SM ;
Gonzalez, C ;
Miettinen, H ;
Kennedy, E ;
Stern, MP .
DIABETES CARE, 1996, 19 (10) :1138-1141
[15]   Cardiovascular morbidity and mortality associated with the metabolic syndrome [J].
Isomaa, B ;
Almgren, P ;
Tuomi, T ;
Forsén, B ;
Lahti, K ;
Nissén, M ;
Taskinen, MR ;
Groop, L .
DIABETES CARE, 2001, 24 (04) :683-689
[16]   Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system [J].
Kurtz, TW ;
Pravenec, M .
JOURNAL OF HYPERTENSION, 2004, 22 (12) :2253-2261
[17]   Effects of losartan on insulin sensitivity in hypertensive subjects [J].
Laakso, M ;
Karjalainen, L ;
LempiainenKuosa, P .
HYPERTENSION, 1996, 28 (03) :392-396
[18]   The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men [J].
Lakka, HM ;
Laaksonen, DE ;
Lakka, TA ;
Niskanen, LK ;
Kumpusalo, E ;
Tuomilehto, J ;
Salonen, JT .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (21) :2709-2716
[19]   Dietary, evolutionary, and modernizing influences on the prevalence of type 2 diabetes [J].
Lieberman, LS .
ANNUAL REVIEW OF NUTRITION, 2003, 23 :345-377
[20]   Importance of smooth and sustained blood pressure control in preventing cardiovascular morbidity and mortality [J].
Mancia, G ;
Parati, G .
BLOOD PRESSURE, 2001, 10 :26-32